drugset / Trial / NCT02660580
MSB11022 in Moderate to Severe Chronic Plaque Psoriasis
Phase 3
Completed
443 enrolled
Fresenius Kabi SwissBioSim GmbH
Merck KGaA, Darmstadt, Germany · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study was to compare the efficacy, safety and immunogenicity of MSB11022 and Humira® in adult subjects with moderate to severe chronic plaque type psoriasis.
Timeline
- Start
- 2016-02-16
- Primary completion
- 2016-12-31
- Completion
- 2017-12-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adalimumab | Monoclonal antibody | 40 mg | Subcutaneous |
| Subject | MSB11022 | Unknown | 40 mg | Subcutaneous |